Profil
Dr. Florian D.
Vogl was previously employed as a Chief Medical Officer by Immutep Ltd., a Chief Medical Officer by Cellestia Biotech AG, and a Head-Clinical Development Europe by Rainier Therapeutics, Inc. He received his doctorate degree from Ludwig-Maximilians-Universität München.
Ehemalige bekannte Positionen von Florian Vogl
| Unternehmen | Position | Ende |
|---|---|---|
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Manufactures anti-cancer drugs | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2023 |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Corporate Officer/Principal | 01.12.2019 |
| IMMUTEP LIMITED | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Florian Vogl
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Immutep Ltd.
Immutep Ltd. BiotechnologyHealth Technology Engages in the development of anti-cancer therapeutics | Health Technology |
Ludwig-Maximilians-Universität München
Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Health Technology |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Manufactures anti-cancer drugs | Health Technology |
















